BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Niaspan niacin: Additional Phase III data

The double-blind, North American Phase III AIM-HIGH trial in 3,414 patients showed that high doses of daily extended-release Niaspan plus Zocor simvastatin missed the primary endpoint of significantly reducing a composite of death from CHD, non-fatal MI, ischemic stroke, hospitalization for ACS or revascularization procedures vs. Zocor alone at a mean follow-up of 3 years (16.4% vs. 16.2%, p=0.79). Niaspan plus Zocor also missed the secondary endpoints of significantly reducing a...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >